(Q50913242)

25 March 2018

title

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. (English)

1 reference

25 March 2018

1 reference

23

Bernard Escudier

1 reference

25 March 2018

Brian Rini

1

1 reference

25 March 2018

Audrey Goddard

2

1 reference

25 March 2018

Dejan Knezevic

3

1 reference

25 March 2018

Tara Maddala

4

1 reference

25 March 2018

Ming Zhou

5

1 reference

25 March 2018

Hakan Aydin

6

1 reference

25 March 2018

Steven Campbell

7

1 reference

25 March 2018

Paul Elson

8

1 reference

25 March 2018

Serge Koscielny

9

1 reference

25 March 2018

Margarita Lopatin

10

1 reference

25 March 2018

Christer Svedman

11

1 reference

25 March 2018

Jean-Francois Martini

12

1 reference

25 March 2018

J Andrew Williams

13

1 reference

25 March 2018

Virginie Verkarre

14

1 reference

25 March 2018

Camelia Radulescu

15

1 reference

25 March 2018

Yann Neuzillet

16

1 reference

25 March 2018

Isabelle Hemmerlé

17

1 reference

25 March 2018

Marc Olivier Timsit

18

1 reference

25 March 2018

Athanasios C Tsiatis

19

1 reference

25 March 2018

Michael Bonham

20

1 reference

25 March 2018

Thierry Lebret

21

1 reference

25 March 2018

Arnaud Mejean

22

1 reference

25 March 2018

publication date

12 May 2015

1 reference

25 March 2018

Lancet Oncology Commission

published in

1 reference

25 March 2018

volume

16

1 reference

25 March 2018

issue

6

1 reference

25 March 2018

page(s)

676-685

1 reference

25 March 2018

The epidemiology of renal cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Adjuvant therapy in renal cell carcinoma-past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

1 reference

7 January 2021

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Improved prognostication of renal cell carcinoma using an integrated staging system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Grading of clear cell renal cell carcinoma should be based on nucleolar prominence.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

A direct approach to false discovery rates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Limited prognostic value of tumor necrosis in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (≤4 cm): an analysis of the SEER database

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

SPOP mutations in prostate cancer across demographically diverse patient cohorts.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970167-1

7 January 2021

10.1016/S1470-2045(15)70167-1

Identifiers

DOI

1 reference

25 March 2018

PubMed ID

25979595

1 reference

25 March 2018